Statins for the treatment of antiphospholipid syndrome

Praveen Jajoria, Vijaya Murthy, Elizabeth Papalardo, Zurina Romay-Penabad, Caroline Gleason, Silvia S. Pierangeli

Research output: Chapter in Book/Report/Conference proceedingConference contribution

41 Citations (Scopus)

Abstract

Fluvastatin has been shown to revert proinflammatoryprothrombotic effects of antiphospholipid antibodies (aPL) in vitro and in mice. Here, we examined whether fluvastatin affects the levels of proinflammatoryprothrombotic markers in antiphospholipid syndrome (APS) patients. Vascular endothelial growth factor (VEGF), soluble tissue factor (sTF), tumor necrosis factor-α (TNF-α), soluble intercellular adhesion molecule-1 (sICAM-1), sE-selectin (E-sel), C-reactive protein (CRP), and soluble vascular cell adhesion molecule (sVCAM-1), were measured in the sera of 93 APS patients and 60 controls and in the sera of nine patients with APS before and after 30 days of treatment with fluvastatin. Elevated levels of VEGF, sTF, and TNF-α were found in APS patients. Fluvastatin significantly reduced those markers in the majority of treated subjects. The data from this study show that statins may be beneficial in aPL-positive patients and warrant larger clinical trials to confirm the efficacy of the drug for the treatment of APS clinical manifestations.

Original languageEnglish (US)
Title of host publicationContemporary Challenges in Autoimmunity
Pages736-745
Number of pages10
Volume1173
DOIs
StatePublished - Sep 2009
Externally publishedYes

Publication series

NameAnnals of the New York Academy of Sciences
Volume1173
ISSN (Print)00778923
ISSN (Electronic)17496632

Fingerprint

fluvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Antiphospholipid Syndrome
Antiphospholipid Antibodies
Thromboplastin
Vascular Endothelial Growth Factor A
Tumor Necrosis Factor-alpha
E-Selectin
Vascular Cell Adhesion Molecule-1
Intercellular Adhesion Molecule-1
Therapeutics
C-Reactive Protein
Serum
Clinical Trials
Pharmaceutical Preparations

Keywords

  • Anticardiolipin antibodies
  • Antiphospholipid antibodies
  • Antiphospholipid syndrome
  • Proinflammatory markers
  • Statins

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Jajoria, P., Murthy, V., Papalardo, E., Romay-Penabad, Z., Gleason, C., & Pierangeli, S. S. (2009). Statins for the treatment of antiphospholipid syndrome. In Contemporary Challenges in Autoimmunity (Vol. 1173, pp. 736-745). (Annals of the New York Academy of Sciences; Vol. 1173). https://doi.org/10.1111/j.1749-6632.2009.04815.x

Statins for the treatment of antiphospholipid syndrome. / Jajoria, Praveen; Murthy, Vijaya; Papalardo, Elizabeth; Romay-Penabad, Zurina; Gleason, Caroline; Pierangeli, Silvia S.

Contemporary Challenges in Autoimmunity. Vol. 1173 2009. p. 736-745 (Annals of the New York Academy of Sciences; Vol. 1173).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Jajoria, P, Murthy, V, Papalardo, E, Romay-Penabad, Z, Gleason, C & Pierangeli, SS 2009, Statins for the treatment of antiphospholipid syndrome. in Contemporary Challenges in Autoimmunity. vol. 1173, Annals of the New York Academy of Sciences, vol. 1173, pp. 736-745. https://doi.org/10.1111/j.1749-6632.2009.04815.x
Jajoria P, Murthy V, Papalardo E, Romay-Penabad Z, Gleason C, Pierangeli SS. Statins for the treatment of antiphospholipid syndrome. In Contemporary Challenges in Autoimmunity. Vol. 1173. 2009. p. 736-745. (Annals of the New York Academy of Sciences). https://doi.org/10.1111/j.1749-6632.2009.04815.x
Jajoria, Praveen ; Murthy, Vijaya ; Papalardo, Elizabeth ; Romay-Penabad, Zurina ; Gleason, Caroline ; Pierangeli, Silvia S. / Statins for the treatment of antiphospholipid syndrome. Contemporary Challenges in Autoimmunity. Vol. 1173 2009. pp. 736-745 (Annals of the New York Academy of Sciences).
@inproceedings{0b2e50ab582c469aa4da67851336579f,
title = "Statins for the treatment of antiphospholipid syndrome",
abstract = "Fluvastatin has been shown to revert proinflammatoryprothrombotic effects of antiphospholipid antibodies (aPL) in vitro and in mice. Here, we examined whether fluvastatin affects the levels of proinflammatoryprothrombotic markers in antiphospholipid syndrome (APS) patients. Vascular endothelial growth factor (VEGF), soluble tissue factor (sTF), tumor necrosis factor-α (TNF-α), soluble intercellular adhesion molecule-1 (sICAM-1), sE-selectin (E-sel), C-reactive protein (CRP), and soluble vascular cell adhesion molecule (sVCAM-1), were measured in the sera of 93 APS patients and 60 controls and in the sera of nine patients with APS before and after 30 days of treatment with fluvastatin. Elevated levels of VEGF, sTF, and TNF-α were found in APS patients. Fluvastatin significantly reduced those markers in the majority of treated subjects. The data from this study show that statins may be beneficial in aPL-positive patients and warrant larger clinical trials to confirm the efficacy of the drug for the treatment of APS clinical manifestations.",
keywords = "Anticardiolipin antibodies, Antiphospholipid antibodies, Antiphospholipid syndrome, Proinflammatory markers, Statins",
author = "Praveen Jajoria and Vijaya Murthy and Elizabeth Papalardo and Zurina Romay-Penabad and Caroline Gleason and Pierangeli, {Silvia S.}",
year = "2009",
month = "9",
doi = "10.1111/j.1749-6632.2009.04815.x",
language = "English (US)",
isbn = "9781573317627",
volume = "1173",
series = "Annals of the New York Academy of Sciences",
pages = "736--745",
booktitle = "Contemporary Challenges in Autoimmunity",

}

TY - GEN

T1 - Statins for the treatment of antiphospholipid syndrome

AU - Jajoria, Praveen

AU - Murthy, Vijaya

AU - Papalardo, Elizabeth

AU - Romay-Penabad, Zurina

AU - Gleason, Caroline

AU - Pierangeli, Silvia S.

PY - 2009/9

Y1 - 2009/9

N2 - Fluvastatin has been shown to revert proinflammatoryprothrombotic effects of antiphospholipid antibodies (aPL) in vitro and in mice. Here, we examined whether fluvastatin affects the levels of proinflammatoryprothrombotic markers in antiphospholipid syndrome (APS) patients. Vascular endothelial growth factor (VEGF), soluble tissue factor (sTF), tumor necrosis factor-α (TNF-α), soluble intercellular adhesion molecule-1 (sICAM-1), sE-selectin (E-sel), C-reactive protein (CRP), and soluble vascular cell adhesion molecule (sVCAM-1), were measured in the sera of 93 APS patients and 60 controls and in the sera of nine patients with APS before and after 30 days of treatment with fluvastatin. Elevated levels of VEGF, sTF, and TNF-α were found in APS patients. Fluvastatin significantly reduced those markers in the majority of treated subjects. The data from this study show that statins may be beneficial in aPL-positive patients and warrant larger clinical trials to confirm the efficacy of the drug for the treatment of APS clinical manifestations.

AB - Fluvastatin has been shown to revert proinflammatoryprothrombotic effects of antiphospholipid antibodies (aPL) in vitro and in mice. Here, we examined whether fluvastatin affects the levels of proinflammatoryprothrombotic markers in antiphospholipid syndrome (APS) patients. Vascular endothelial growth factor (VEGF), soluble tissue factor (sTF), tumor necrosis factor-α (TNF-α), soluble intercellular adhesion molecule-1 (sICAM-1), sE-selectin (E-sel), C-reactive protein (CRP), and soluble vascular cell adhesion molecule (sVCAM-1), were measured in the sera of 93 APS patients and 60 controls and in the sera of nine patients with APS before and after 30 days of treatment with fluvastatin. Elevated levels of VEGF, sTF, and TNF-α were found in APS patients. Fluvastatin significantly reduced those markers in the majority of treated subjects. The data from this study show that statins may be beneficial in aPL-positive patients and warrant larger clinical trials to confirm the efficacy of the drug for the treatment of APS clinical manifestations.

KW - Anticardiolipin antibodies

KW - Antiphospholipid antibodies

KW - Antiphospholipid syndrome

KW - Proinflammatory markers

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=70049117028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70049117028&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2009.04815.x

DO - 10.1111/j.1749-6632.2009.04815.x

M3 - Conference contribution

C2 - 19758223

AN - SCOPUS:70049117028

SN - 9781573317627

VL - 1173

T3 - Annals of the New York Academy of Sciences

SP - 736

EP - 745

BT - Contemporary Challenges in Autoimmunity

ER -